ReviewJournal of oncology2021

LSD1 as a Biomarker and the Outcome of Its Inhibitors in the Clinical Trial: The Therapy Opportunity in Tumor.

Clement Agboyibor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.